Raloxifene

• Osteoporosis Prevention and Treatment
• Breast Cancer Risk Reduction
• Postmenopausal Bone Health

Raloxifene is an oral selective estrogen receptor modulator (SERM) used both for prevention and treatment of postmenopausal osteoporosis and for reducing the risk of invasive breast cancer in higher-risk postmenopausal women. Marketed as Evista, it occupies a unique position in women's health because its estrogen-like effects on bone and lipids coexist with anti-estrogenic effects on breast and neutral effects on the uterus. The dual benefit makes raloxifene appealing for selected patients, but it carries a boxed warning for venous thromboembolism and for stroke mortality in women with established cardiovascular disease, requiring careful patient selection.

Mechanism of Action

Raloxifene is a benzothiophene SERM that binds with high affinity to both estrogen receptor alpha and beta but produces tissue-specific effects depending on local cofactor recruitment. In bone, raloxifene acts as an estrogen agonist: it suppresses osteoclast activity, slows resorption, and promotes a positive bone balance, raising spine bone mineral density by roughly 2 to 3 percent over three years. In breast tissue, raloxifene acts as an estrogen antagonist, blocking estrogen-driven proliferation of estrogen receptor-positive ductal cells and substantially reducing the risk of invasive ER-positive breast cancer.

In the uterus, raloxifene is largely neutral, neither stimulating endometrial proliferation (unlike unopposed estrogen) nor causing endometrial atrophy. This is a major advantage over tamoxifen, which is an endometrial agonist and can cause endometrial hyperplasia and cancer. On lipids, raloxifene partially mimics estrogen, lowering total and LDL cholesterol modestly without raising triglycerides as oral estrogen does. The thrombotic risk that accompanies estrogen — a roughly two- to threefold increase in venous thromboembolism — is preserved, which is the basis of the boxed warning. The MORE and CORE trials established the dual bone and breast cancer benefits, and the RUTH trial defined the cardiovascular profile in women at risk for coronary disease. The Bone Health and Osteoporosis Foundation and American Cancer Society summarize SERM use for both indications.

Clinical Use

FDA-approved indications include prevention and treatment of postmenopausal osteoporosis and reduction of invasive breast cancer risk in postmenopausal women with osteoporosis or with high breast cancer risk based on Gail score or family history. In osteoporosis, raloxifene is generally considered when bisphosphonates such as alendronate, risedronate, ibandronate, or zoledronic acid are contraindicated, not tolerated, or when the patient has co-existing elevated breast cancer risk that argues for the SERM's dual benefit. Raloxifene is less effective at hip fracture prevention than bisphosphonates, so it is not the first choice when hip fracture risk dominates. For severe osteoporosis with multiple vertebral fractures or very low T-scores, anabolic agents like teriparatide, abaloparatide, or romosozumab are preferred.

In breast cancer prevention, raloxifene and tamoxifen both reduce ER-positive breast cancer risk by roughly 50 percent in high-risk postmenopausal women. The STAR trial showed raloxifene caused fewer endometrial cancers and thromboembolic events than tamoxifen, but slightly less reduction in non-invasive breast cancer. Risk-benefit discussions, often using the USPSTF breast cancer chemoprevention recommendations, guide the choice. Raloxifene is not used in premenopausal women, men, or women with a personal history of venous thromboembolism. Reading bone health after 50 helps patients prepare for these decisions.

How to Take It

Raloxifene is taken as a single 60 mg tablet once daily, with or without food, at any consistent time. Tablets are swallowed whole with water. A missed dose is taken when remembered the same day; if it is closer to the next dose, the missed dose is skipped — do not double up. Tablets are stored at room temperature in the original container.

Patients should ensure adequate calcium (1,200 mg daily total from diet plus supplements) and vitamin D (800 to 1,000 IU daily) intake while on raloxifene. Cholestyramine, taken for cholesterol or bile acid binding, reduces raloxifene absorption by 60 percent and should not be used together. Levothyroxine absorption can be modestly reduced; separating dosing by at least four hours is reasonable. Warfarin effect may be slightly diminished, so INR is checked more often after initiation.

In the first weeks, hot flashes are the most common bothersome effect, occurring in roughly 25 percent of women, typically improving with time. Leg cramps, mild peripheral edema, or flu-like symptoms may also occur. Critically, raloxifene must be discontinued at least 72 hours before any planned prolonged immobilization — major surgery, casting, or extended bed rest — and not resumed until full ambulation is restored, because of the elevated venous thromboembolism risk. Long airline flights also warrant standard prophylactic measures including hydration, walking, and compression stockings.

Monitoring and Follow-Up

Before initiation, history should screen for prior DVT, pulmonary embolism, retinal vein occlusion, established coronary disease, or stroke — any of which generally precludes use. Baseline DXA confirms osteoporosis, and a pregnancy test is needed if any uncertainty about menopausal status exists. Lipid panel and liver enzymes are reasonable. Mammography per USPSTF guidance is established before starting raloxifene for breast cancer risk reduction.

During therapy, DXA is repeated every one to two years to confirm stable or improving spine bone mineral density. Annual mammography continues. Lipid panel rechecks confirm the modest LDL-lowering effect — many patients still benefit from reading the statin guide. Any unexplained vaginal bleeding warrants prompt gynecologic evaluation; raloxifene is not associated with endometrial cancer risk, but unexplained bleeding always deserves workup. Calf swelling, sudden chest pain, shortness of breath, or visual changes require immediate evaluation for thrombosis or stroke.

Special Populations

Raloxifene is contraindicated in pregnancy (Category X) and in lactation, with potential to cause fetal harm based on animal data. It is not indicated or studied in premenopausal women. Men do not have an indication for raloxifene. Mild hepatic impairment requires no formal adjustment, but plasma levels increase substantially in moderate impairment and use should be cautious; severe impairment is generally avoided. Mild to moderate renal impairment requires no dose adjustment; severe impairment should be approached cautiously. Elderly patients tolerate raloxifene similarly to younger postmenopausal women but face a higher absolute thromboembolic risk that informs shared decision-making, particularly above age 75.

When to Contact Your Doctor

Seek emergency care for sudden chest pain, shortness of breath, painful unilateral leg swelling, severe headache, slurred speech, facial droop, or sudden vision loss — these may indicate pulmonary embolism, deep vein thrombosis, stroke, or retinal vein occlusion. Call promptly for any unexplained vaginal bleeding, persistent breast lump or change, severe leg cramps that disrupt sleep, or new lower extremity swelling without obvious cause. Discuss any planned surgery, prolonged travel, or extended bed rest in advance so raloxifene can be paused safely. New medications, particularly cholestyramine or warfarin, should be reviewed with the prescriber. If menopausal symptoms become intolerable, a discussion about alternatives is reasonable rather than self-discontinuation.

Cost and adherence are practical considerations: raloxifene is available generically, with consistent once-daily dosing that most patients find easy to maintain. Unlike bisphosphonates, it does not require timing around meals, calcium, or other medications, and there is no requirement to remain upright after dosing — making it appealing for patients who struggle with the strict administration rules of oral bisphosphonates or who have esophageal disease that contraindicates them. Lifestyle factors substantially influence both bone health and breast cancer risk during raloxifene therapy. Maintaining a healthy weight, limiting alcohol to no more than one drink daily, regular weight-bearing and resistance exercise, smoking cessation, and adequate dietary protein all support the medication's bone benefits. Postmenopausal women in St. Petersburg also benefit from annual skin examinations and adherence to age-appropriate screening for colorectal, lung (in eligible smokers), and cervical cancer per USPSTF recommendations. Vasomotor symptoms that worsen on raloxifene can sometimes be managed with non-hormonal options including selective serotonin reuptake inhibitors, gabapentin, or cognitive behavioral therapy rather than discontinuing therapy. Patients planning travel involving long flights should walk the aisle every hour or two, stay well hydrated, and consider graduated compression stockings — simple measures that meaningfully reduce thrombotic risk on a SERM. Reading the bone health overview puts treatment choices in broader context.

For an individualized review of bone density, breast cancer risk, and the right treatment strategy in St. Petersburg, contact us or schedule a visit with our internal medicine team.